Document Detail

Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
MedLine Citation:
PMID:  12817430     Owner:  NLM     Status:  MEDLINE    
Although some studies have examined the expression of aberrant markers such as CD2, CD7, CD10, CD13, CD33, and CD34 on B cells in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a uniform multiparametric analysis of the frequency of expression of these markers using stringent criteria is lacking. By using 3-color flow cytometry, we analyzed 117 cases (bone marrow, 71; blood, 31; lymph nodes, 15) for coexpression of aberrant markers with CD19. Marker expression was considered positive when present on at least 20% of CD19+ cells. Of 117 cases, 40 (34.2%) showed expression of 1 or more aberrant markers. Expression of 4 aberrant markers was seen in 1 case, 3 in 4 cases, 2 in 15 cases, and 1 in 20 cases. Kaplan-Meier survival curves and the log-rank test revealed that the group with aberrant markers showed significantly shortened overall survival compared with the group without aberrant markers (P < .001). There is considerable phenotypic heterogeneity in CLL/SLL, and expression of aberrant markers indicates aggressiveness.
Bal Kampalath; Maurice P Barcos; Carleton Stewart
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical pathology     Volume:  119     ISSN:  0002-9173     ISO Abbreviation:  Am. J. Clin. Pathol.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-23     Completed Date:  2003-07-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370470     Medline TA:  Am J Clin Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  824-32     Citation Subset:  AIM; IM    
Dept of Pathology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal
Antigens, CD / analysis
Antigens, CD13 / analysis
Antigens, CD19 / analysis
Antigens, CD2 / analysis
Antigens, CD34 / analysis
Antigens, CD7 / analysis
Antigens, Differentiation, Myelomonocytic / analysis
B-Lymphocytes / immunology*
Bone Marrow / immunology
Flow Cytometry
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*,  mortality
Lymph Nodes / immunology
Middle Aged
Neprilysin / analysis
Survival Rate
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Antigens, CD19; 0/Antigens, CD2; 0/Antigens, CD34; 0/Antigens, CD7; 0/Antigens, Differentiation, Myelomonocytic; 0/CD33 antigen; EC, CD13; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rhabdomyomatous multilocular thymic cyst.
Next Document:  Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathol...